Our Team

Stelvio Oncology has developed an epigenetic signature based platform for identifying compounds that drive differentiation of cancer stem cells into benign cell types.

Attila Hajdu, MBA, MSc, Chief Executive Officer, Founder, STELVIO ONCOLOGY

Alexey V. Terskikh, Ph.D., Co-Founder, STELVIO ONCOLOGY
Associate Professor, Development, Aging and Regeneration Program
Sanford Burnham Prebys Medical Discovery Institute

David Andrews, PhD
Director of Biological Sciences, Professor of Biochemistry,
University of Toronto

David Spaner, MD, PhD
Medical Oncologist/Hematologist, Senior Scientist,
Sunnybrook Health Sciences Centre

About our team

Stelvio Oncology has core competencies of scientific creativity, clinical excellence and professional management required to successfully commercialize novel drug therapies and precision medicine diagnostics.

Bio (adsbygoogle = window.adsbygoogle || []).push({});

Bio (adsbygoogle = window.adsbygoogle || []).push({});

“It's more important to know what sort of person has a disease than what sort of disease a person has.”–Hippocrates (adsbygoogle = window.adsbygoogle || []).push({});

Our Team (adsbygoogle = window.adsbygoogle || []).push({});

Our Team (adsbygoogle = window.adsbygoogle || []).push({});

About our team (adsbygoogle = window.adsbygoogle || []).push({});

Bio

Bio

“It's more important to know what sort of person has a disease than what sort of disease a person has.”
–Hippocrates

Our Team

Our Team

About our team